Latest News From Lumira Ventures

Antios Therapeutics Initiates First-in-Human Phase 1 Study of ATI-2173

Jennifer Schram Antios Therapeutics, Portfolio News, Press Release

ATLANTA /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its first-in-human Phase 1 clinical trial for ATI-2173, a novel liver-targeted, orally-administered, …